Concurrent chemoradiotherapy with S-1 for T2N0 Glottic squamous cell carcinoma

Journal of Radiation Research

Volumn 51, Issue 4, 2010, Pages 481-484

  Nonoshita, Takeshi ^a   Shioyama, Yoshiyuki ^a   Nakamura, Katsumasa ^b   Nakashima, Torahiko ^a   Ohga, Saiji ^a   Yoshitake, Tadamasa ^a   Ohnishi, Kayoko ^a   Terashima, Kotaro ^a   Asai, Kaori ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIOTHERAPY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; RADIOTHERAPY;

CONCURRENT CHEMORADIOTHERAPY; CONTROL RATES; FOLLOW UP; GLOTTIC CARCINOMAS; INITIAL LOCAL CONTROL; LOCAL CONTROL; MUCOSITIS; SQUAMOUS CELL CARCINOMA; TEGAFUR; UP PERIOD;

TOXICITY;

EID: 77954995293     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.09134     Document Type: Article

References (22)

1. Howell-Burke D, et al (1990) T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. Arch Otolaryngol Head Neck Surg 116: 830-851.
2. Inoue T, et al (1992) Prognostic factor of telecobalt therapy for early glottic carcinoma. Cancer 70: 2797-2801.
3. Le QT, et al (1997) Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 39: 115-126.
4. Mendenhall WM, et al (2001) T1-2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19: 4029-4036.
5. Itoh Y and Fuwa N (2006) Concurrent chemoradiotherapy using protracted continuous infusion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Radiat Med 24: 277-281.
6. Akimoto T, et al (2006) Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control. Int J Radiat Oncol Biol Phys 15: 64: 995-1001.
7. Niibe Y, et al (2007) Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan. Anticancer Res 27: 3497-3500.
8. Nishimura G, et al (2009) Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation. Anticancer Res 29: 661-666.
9. Harada K, et al (2005) S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 226: 161-168.
10. Zeng L, et al (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99: 2327-2335.
11. Harada K, Ferdous T and Yoshida H (2007) Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma. Oncol Rep 18: 1077-1083.
12. Tsukuda M, et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64: 945-952.
13. Barton MB, et al (1992) The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol 23: 137-143.
14. Harwood AR, et al (1981) T2 glottic cancer: an analysis of dose-time-volume factors. Int J Radiat Oncol Biol Phys 7: 1501-1505.
15. Akine Y, et al (1991) Radiotherapy of T1 glottic cancer with 6 MeV X rays. Int J Radiat Oncol Biol Phys 20: 1215-1218.
16. Mendenhall WM, et al (2004) Management of T1-T2 glottic carcinomas. Cancer 100: 1786-1792.
17. Frata P, et al (2005) Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys 63: 1387-1394.
18. Shirasaka T, et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557.
19. Kim HM, et al (2009) Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 63: 535-541.
20. Cho SH, et al (2008) Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 21: 697-703.
21. Kawahara M, et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943.
22. Tsuji H, et al (2006) A phase I study of concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma. Oncology 71: 369-373.